САЩ лицензира първата комбинирана таблетка за безинтерфероново лечение на хепатит С - Harvoni

На 10 октомври 2014 г. Американската агенция за храните и лекарствата издаде разрешение за употреба на медкамента Harvoni (ledipasvir 90 мг/sofosbuvir 400 мг) – първата комбинирана таблетка за еднократен дневен перорален прием за лечение на хроничен хепатит С (HCV) при възрастни, инфектирани с генотип 1 на вируса. 

Harvoni е комбинация от ledipasvir - NS5A инхибитор, и sofosbuvir - нуклеотиден аналогов полимеразен NS5B инхибитор. Sofosbuvir е разрешен за употреба под търговското име Sovaldi през декември 2013 г. в САЩ и през януари тази година в Европа.

Harvoni е първата комбинирана таблетка, която получава разрешение за употреба за лечение на хроничен хепатит С генотип 1. Освен това е първата лечебна комбинация, която не изисква прием с интерферон или ribavirin – два други медикамента, използвани за лечение на хроничен хепатит С. И двата медикамента в състава на Harvoni взаимодействат с ензими, необходими за репликацията на HCV.

Ефикасността на Harvoni е установена при пациенти с HCV генотип 1, при които лечението продължава 8, 12 или 24 седмици в зависимост от предишни провеждани терапии, състояние по отношение на цирозата и изходния вирусен товар. Продължителност на лечение от 8 седмици с Harvoni може да се обмисля при терапевтично наивни пациенти без цироза с изходен вирусен товар за HCV под 6 милиона IU/mL.

В хода на трите клинични проучвания Фаза 3 (ION-1, ION-2 и ION-3) за изпитване на медикамента, Harvoni постига степен на излекуване (SVR12) от 94-99%.

Източник: Gilead Sciences

[ Прочети още... ]

Публикувана от rosen -сряда, 15 октомври 2014 - 09:45:48изглед за печат

Inventing the end of AIDS is premature and dangerous

A blog by Sisonke Msimang, editor and lead-writer of our new publication AIDS Today: Tell no lies and claim no easy victories.

We have reached a critical juncture in the story of AIDS. The headline news is that the world is on the brink of ending this enduring epidemic. Like many others who have dedicated their lives to battling this deadly disease, I hope this will be true one day. But this is no time for complacency.

There are still 35 million people globally who are living with HIV in their bodies. There are still daily assaults on the rights and dignity of women, girls and people who are gay, transgendered, sex workers, prisoners or drug users. And the structural drivers of inequality and injustice that have always shaped this disease remain firmly in place 30 years into this epidemic. The war on AIDS is not over yet.

In recent years, I have had many misgivings about the state of the AIDS response. I have watched with growing disquiet as the Joint United Nations Programme on HIV/AIDS (UNAIDS) has published its global report on the state of AIDS each year, increasingly taking on the voice of a cheerleader, applauding country efforts, commending progress and being the bearer of good news.

Source: http://www.aidsalliance.org

[ Прочети още... ]

Публикувана от rosen -понеделник, 13 октомври 2014 - 10:07:34изглед за печат

AIDS Today: Tell no lies and claim no easy victories

AIDS Today: Tell no lies and claim no easy victories is the first edition of our new biennial publication that presents the global state of the civil society response to AIDS.

The report aims to spark a timely debate about the global AIDS response: what it has achieved, what it can teach others fighting for health and justice, and what remains to be done to bring about a sustainable end to AIDS.

Edited by South African writer and activist, Sisonke Msimang, AIDS Today contains nine powerful essays from leading figures in the AIDS response from Latin America, Africa, Europe, America and Asia.

Each of the nine essays are meditations on winning and losing in the HIV response, for example the story of how Uganda went from being “the darling of the AIDS world to its pariah”. In another, the author concludes that through “strategic blunders, complacency and a focus on other issues that also require attention and activism,” activists have taken their eye off the ball when it comes to drug prices and trade barriers blocking drug access.

Msimang said: “In reaching out to a group of thoughtful, tough and astute activists, we have inadvertently tapped into a raging counter-narrative that seemed to have had no formal outlet until now. Taken together these essays represent a wail against complacency, a battle cry in defence of human rights in an era of jargon and statistics.

Source: http://aidsalliance.org

[ Прочети още... ]

Публикувана от rosen -понеделник, 13 октомври 2014 - 10:01:01изглед за печат

Antiretroviral therapy benefits HIV-infected stimulant users

New clinical research from UC San Francisco shows that 341 HIV-infected men who reported using stimulants such as methamphetamine or cocaine derived life-saving benefits from being on antiretroviral therapy that were comparable to those of HIV-infected men who do not use stimulants.

That said, those who reported using stimulants at more than half of at least two study visits did have modestly increased chances of progressing to AIDS or dying after starting antiretroviral therapy compared to non-users. The data was collected between 1996 and 2012.

"Patients with HIV who use stimulants and other substances often experience difficulties with accessing antiretroviral therapy, partially due to the concerns of healthcare providers that they will not be able take their medications as directed. Findings from this study demonstrate that many stimulant users take their antiretroviral therapy at levels sufficient to avoid negative clinical outcomes. When we look at overall mortality, antiretroviral therapy leads to similar clinical benefits for both stimulant users and non-users, notwithstanding stimulant use," said the study's primary investigator, Adam W. Carrico, PhD., UCSF assistant professor of nursing.

The research is available starting in October online ahead of print in the Journal of Acquired Immune Deficiency Syndromes. The study included 1,313 HIV-infected men who have sex with men within the Multicenter AIDS Cohort Study, an ongoing nationwide prospective study of HIV infection among men who have sex with men in the U.S.

Source: University of California, San Francisco (UCSF)

[ Прочети още... ]

Публикувана от rosen -петък, 10 октомври 2014 - 13:41:42изглед за печат

Response to UKIP leader's discriminatory remarks

The International HIV/AIDS Alliance is appalled by the discriminatory statements made by UKIP leader Nigel Farage about people living with HIV being barred from entry to the UK.

Not only are Mr. Farage’s comments hugely stigmatizing, they are also out of date and show a complete lack of understanding of the issues.

Whilst there are many countries around the world that restrict the entry, residence and stay of foreigners who are HIV positive, these countries are simply perpetuating stigma and discrimination against people living with HIV by singling out HIV as a “dangerous disease”.

In recognition of the fact that such entry restrictions have no impact on the HIV epidemic, the US removed them in January 2010. And to the UK’s credit no government in the last thirty years has ever put in place border controls against people living with HIV.

Reacting to Farage’s remarks, Alvaro Bermejo, Executive Director of the Alliance, said: “As a UK-based international organisation whose quality of work and global leadership depends on being able to recruit people from communities most vulnerable to HIV, whether living with HIV or not, we strongly condemn his comments.”

Source: http://www.aidsalliance.org/

Публикувана от rosen -петък, 10 октомври 2014 - 09:56:08изглед за печат

Отиди на страница       >>